go-v.orgdoi

Clinicopathologic characteristics and survival outcome in patients with advanced lung adenocarcinoma and KRAS mutation

Shifeng Yang, Xinmin Yu, Yun Fan, Xun Shi, Ying Jin · Journal of Cancer · 2018

  • DOI 10.7150/jca.24425
  • Publisher Ivyspring International Publisher
  • Type article
  • Issued 2018

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

Journal of Cancer · Ivyspring International Publisher · article · 2018

Abstract

Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations are one of the most common observed genetic events in lung adenocarcinoma.The present study aimed to characterize treatment patterns and to estimate survival for patients in China with advanced lung adenocarcinoma and KRAS mutation.We identified KRAS-mutant lung adenocarcinoma between February 2013 and June 2017 in Zhejiang Cancer Hospital.Patients' characteristics and treatment outcomes were analyzed.A total of 159 lung adenocarcinoma were included, and 26 (16.4%) patients harbored KRAS mutations.Compared to KRAS-wild patients, patients with KRAS-mutant tumors were more likely to be smokers (76.9% vs.

51.9%,P = 0.029).Median tumor mutation burden (TMB) was significantly higher in the KRAS-mutant cohort than in the KRAS-wild cohort (5.4 vs. 4.2 mutations/megabases; P=0.041).Of the 93 patients receiving first-line chemotherapy, the median progression-free survival (PFS) in the KRAS-mutant group was significantly shorter than in the KRAS-wild group (1.5 vs.

7.2 months; P<0.001).The median overall survival (OS) in the KRAS-mutant group was also significantly shorter than in the KRAS-wild group (hazard ratio for progression or death for patients with KRAS mutation, 3.260; 95% CI, 1.516 to 7.013; P=0.001).In summary, our findings have several important implications for the molecular characterization and therapeutic outcome of lung adenocarcinoma initiated by oncogenic KRAS.Since the number of KRAS-mutant lung cancer is considerable, it should be taken seriously in clinical diagnosis and treatment.KRAS-mutant lung adenocarcinoma was not sensitive to chemotherapy, new and effective drugs targeting the KRAS pathway are in urgent need.

Open the resolved locator · 10.7150/jca.24425

Metadata licence: OpenAlex metadata (CC0)

Registry
OpenAlex DOI index + API
Fetched
2026-11-19 21:13 UTC
Cache state
not cached yet (bulk-index+openalex)
Locator
https://www.jcancer.org/v09p2930.htm
Metadata licence
OpenAlex metadata (CC0)
Scope
Metadata as returned by the resolver; abstracts are never generated here.